Abstract
This best-selling Marketdata study is a comprehensive analysis of the
fragmented but sizeable $47 billion U.S. clinical lab testing business. The
industry is poised for moderate growth to 2012, as the U.S. population ages
and new tests are developed. Higher margin esoteric and anatomic pathology
tests are pacing growth and the large chains have made a string of
acquisitions in this space, to "buy" growth. International expansion could be
the next growth frontier.
The study examines, in detail, the major test segments: PAP tests,
workplace drug screening, and esoteric tests. An entire chapter is devoted to
the high-growth $5 billion "esoteric" or reference test market-its size,
growth, nature, profiles of all key competitors, with revenue rankings.
Complete analysis of independent commercial labs, hospital labs, and
physician office labs-how they differ and compete, discussion of major
industry trends and demand factors, extensive national/state operating
ratios/latest Census and CLIA data. Analysis of industry receipts from
1980-2005 actual, 2006-2007 performance and outlook, 2012 5-year
forecasts, lab staff salaries and vacancy rates, insurance industry
testing, latest trade journal survey findings. Estimates and opinions of
multiple brokerage firms. Competitor profiles for: Quest Diagnostics,
Lab Corp. of America Holdings, Bio-Reference Labs, American Esoteric Labs,
Ameripath, ARUP, Genzyme, Medtox Scientific, Clinical Pathology Labs, Mayo
Medical Labs, Spectrum Lab Network, Sonora Quest Labs, and more. Contains
reference directory of industry sources, list of 48 NIDA-certified drug test
labs. This study contains 120 tables and charts, and is also sold by chapters.
It is available via several commercial databases as well. Call for chapter
prices.
| 
View Cart
